Barbara A Konkle

List of Publications by Year
in descending order

226	13,270	53794 45	25787 108
papers	citations	h-index	g-index

239	239	239	14579
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis. New England Journal of Medicine, 2008, 358, 2240-2248.	27.0	1,941
2	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 2006, 12, 342-347.	30.7	1,865
3	Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature, 2021, 590, 290-299.	27.8	1,069
4	Mean platelet volume as a predictor of cardiovascular risk: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2010, 8, 148-156.	3.8	813
5	Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage. New England Journal of Medicine, 2010, 362, 600-613.	27.0	563
6	Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature, 2020, 586, 763-768.	27.8	376
7	Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis, 2007, 5, 1904-1913.	3.8	320
8	Prevalence of Heparin-Associated Antibodies Without Thrombosis in Patients Undergoing Cardiopulmonary Bypass Surgery. Circulation, 1997, 95, 1242-1246.	1.6	293
9	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances, 2021, 5, 280-300.	5.2	246
10	The HIT Expert Probability (HEP) Score: a novel preâ€test probability model for heparinâ€induced thrombocytopenia based on broad expert opinion. Journal of Thrombosis and Haemostasis, 2010, 8, 2642-2650.	3.8	229
11	Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood, 2015, 126, 1078-1085.	1.4	224
12	Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data. Nature Genetics, 2022, 54, 263-273.	21.4	156
13	Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. Nature Genetics, 2020, 52, 969-983.	21.4	146
14	Identification of a patient with Bernard-Soulier syndrome and a deletion in the DiGeorge/Velo-cardio-facial chromosomal region in 22q11.2. Human Molecular Genetics, 1995, 4, 763-766.	2.9	144
15	Identification of a Mutation in a GATA Binding Site of the Platelet Glycoprotein Ibî² Promoter Resulting in the Bernard-Soulier Syndrome. Journal of Biological Chemistry, 1996, 271, 22076-22080.	3.4	134
16	Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. American Journal of Obstetrics and Gynecology, 2009, 201, 12.e1-12.e8.	1.3	130
17	Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury. Blood, 2015, 125, 2151-2159.	1.4	127
18	Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 3723-3727.	7.1	126

#	Article	IF	Citations
19	Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood, 2020, 136, 759-762.	1.4	124
20	Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia, 2015, 21, 81-87.	2.1	98
21	Longâ€term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia, 2016, 22, 72-80.	2.1	98
22	Congenital factor VII deficiency: therapy with recombinant activated factor VII - a critical appraisal. Haemophilia, 2006, 12, 19-27.	2.1	97
23	BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood, 2021, 137, 763-774.	1.4	94
24	Secondary prophylaxis with recombinant activated factor VII improves healthâ€related quality of life of haemophilia patients with inhibitors. Haemophilia, 2008, 14, 466-475.	2.1	85
25	Acquired Disorders of Platelet Function. Hematology American Society of Hematology Education Program, 2011, 2011, 391-396.	2.5	84
26	Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia, 2014, 20, 294-300.	2.1	84
27	Activated Protein C Resistance, Factor V Leiden, and Central Retinal Vein Occlusion in Young Adults. JAMA Ophthalmology, 1998, 116, 577.	2.4	83
28	Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Advances, 2017, 1, 824-834.	5.2	83
29	The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression.. Journal of Clinical Investigation, 1988, 82, 579-585.	8.2	82
30	BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. New England Journal of Medicine, 2020, 383, 1018-1027.	27.0	76
31	Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood, 2005, 107, 892-897.	1.4	74
32	High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood, 2016, 127, 637-645.	1.4	73
33	Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia, 2011, 17, 6-13.	2.1	71
34	The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Advances, 2018, 2, 2136-2144.	5.2	69
35	A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. Nature Genetics, 2021, 53, 1504-1516.	21.4	69
36	Fresh frozen plasma prepared with amotosalen HCl (Sâ€59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion, 2005, 45, 1362-1372.	1.6	65

#	Article	IF	Citations
37	Emerging clinical concerns in the ageing haemophilia patient. Haemophilia, 2009, 15, 1197-1209.	2.1	61
38	Pharmacokinetics and safety of OBIâ€1, a recombinant B domainâ€deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia, 2012, 18, 798-804.	2.1	61
39	Human Endothelial Cells in Culture and In Vivo Express on Their Surface All Four Components of the Glycoprotein Ib/IX/V Complex. Blood, 1997, 90, 2660-2669.	1.4	58
40	Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factorÂXa-correlated activated partial thromboplastin time. Journal of Thrombosis and Haemostasis, 2009, 7, 80-86.	3.8	58
41	Characterization of High-Risk HIV-1 Seronegative Hemophiliacs. Clinical Immunology, 2001, 98, 200-211.	3.2	56
42	Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion, 2003, 43, 390-394.	1.6	54
43	Thrombotic Disorders: Diagnosis and Treatment. Hematology American Society of Hematology Education Program, 2003, 2003, 520-539.	2.5	53
44	Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagulation and Fibrinolysis, 2008, 19, 276-282.	1.0	53
45	Preanalytical conditions that affect coagulation testing, including hormonal status and therapy. Journal of Thrombosis and Haemostasis, 2007, 5, 855-858.	3.8	49
46	Clinical outcomes in a cohort of patients with heparinâ€induced thrombocytopenia. American Journal of Hematology, 2017, 92, 730-738.	4.1	49
47	Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 669-674.	3.9	48
48	The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A. Haemophilia, 2011, 17, 196-203.	2.1	47
49	Complex Changes in von Willebrand Factor-Associated Parameters Are Acquired during Uncomplicated Pregnancy. PLoS ONE, 2014, 9, e112935.	2.5	47
50	Role of exercise and physical activity on haemophilic arthropathy, fall prevention and osteoporosis. Haemophilia, 2011, 17, e870-6.	2.1	46
51	Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia, 2020, 26, 494-502.	2.1	44
52	Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2003, 18, 51-54.	1.3	43
53	Rituximab for treatment of inhibitors in haemophilia A. Thrombosis and Haemostasis, 2014, 112, 445-458.	3.4	43
54	A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Advances, 2018, 2, 1325-1333.	5.2	43

#	Article	IF	Citations
55	Complementary DNA cloning of the alternatively expressed endothelial cell glycoprotein Ib beta (GPIb) Tj ETQq1 1 0.784314 rgBT /Ov 93, 2417-2424.	8.2	43
56	Hemophilia trials in the twentyâ€first century: Defining patient important outcomes. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 184-192.	2.3	42
57	Phenotypic Expressions of CCR5-Î”32/Î”32 Homozygosity. Journal of Acquired Immune Deficiency Syndromes, 1999, 22, 75.	0.3	41
58	Novel diagnostic assays for heparin-induced thrombocytopenia. Blood, 2013, 121, 3727-3732.	1.4	41
59	Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. Nature Communications, 2020, 11, 6417.	12.8	39
60	Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. International Journal of Women's Health, 2013, 5, 233.	2.6	38
61	Von Willebrand factor for menorrhagia: a survey and literature review. Haemophilia, 2016, 22, 397-402.	2.1	37
62	Recognizing the need for personalization of haemophilia patientâ€reported outcomes in the prophylaxis era. Haemophilia, 2016, 22, 825-832.	2.1	36
63	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. Science Advances, 2022, 8, eabl6579.	10.3	36
64	Cysteine Disulfides (Cys-ss-X) as Sensitive Plasma Biomarkers of Oxidative Stress. Scientific Reports, 2019, 9, 115.	3.3	35
65	Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Annals of Thoracic Surgery, 2001, 71, 1920-1924.	1.3	34
66	Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project. Haemophilia, 2018, 24, 87-94.	2.1	32
67	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
68	Aging among persons with hemophilia: contemporary concerns. Seminars in Hematology, 2016, 53, 35-39.	3.4	31
69	Thrombotic Thrombocytopenic Purpura: A Paradigm Shift?. Thrombosis and Haemostasis, 2000, 84, 528-535.	3.4	30
70	Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2005, 55, 497-501.	2.3	30
71	Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia, 2009, 15, 918-925.	2.1	30
72	Genome sequencing unveils a regulatory landscape of platelet reactivity. Nature Communications, 2021, 12, 3626.	12.8	29

#	Article	IF	Citations
73	Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed. Cell Genomics, 2022, 2, 100084.	6.5	29
74	World Federation of Hemophilia Gene Therapy Registry. Haemophilia, 2020, 26, 563-564.	2.1	28
75	When should prophylaxis therapy in inhibitor patients be considered?. Haemophilia, 2011, 17, e849-57.	2.1	26
76	Antithrombin Concentrates Use in Children on Extracorporeal Membrane Oxygenation. Pediatric Critical Care Medicine, 2015, 16, 264-269.	0.5	26
77	Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression. Blood, 1998, 91, 3800-3807.	1.4	26
78	Genetic Predisposition to Bleeding during Oral Anticoagulant Therapy: Evidence for Common Founder Mutations (FIXVal-10 and FIXThr-10) and an Independent CpG Hotspot Mutation (FIXThr-10). Thrombosis and Haemostasis, 2001, 85, 454-457.	3.4	25
79	Low-molecular-weight heparin to prevent postpartum venous thromboembolism. Thrombosis and Haemostasis, 2015, 113, 212-216.	3.4	25
80	Clinical challenges within the aging hemophilia population. Thrombosis Research, 2011, 127, S10-S13.	1.7	24
81	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	3.8	24
82	The aging patient with hemophilia. American Journal of Hematology, 2012, 87, S27-32.	4.1	23
83	Management of hereditary antithrombin deficiency in pregnancy. Thrombosis Research, 2017, 157, 41-45.	1.7	23
84	von Willebrand Factor and Aging. Seminars in Thrombosis and Hemostasis, 2014, 40, 640-644.	2.7	22
85	Prophylaxis in real life scenarios. Haemophilia, 2014, 20, 106-113.	2.1	22
86	Low molecular weight heparin to prevent postpartum venous thromboembolism: A pilot study to assess the feasibility of a randomized, open-label trial. Thrombosis Research, 2016, 142, 17-20.	1.7	22
87	A single-center experience of preemptive anticoagulation for patients with risk factors for allograft thrombosis in renal transplantation. Clinical Nephrology, 2010, 74, 351-357.	0.7	22
88	SacI RFLP in the human von Willebrand factor gene. Nucleic Acids Research, 1987, 15, 6766-6766.	14.5	21
89	Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT). Journal of Thrombosis and Haemostasis, 2009, 7, 249-252.	3.8	21
90	Factor VIII mutation and desmopressinâ€responsiveness in 62 patients with mild haemophilia A. Haemophilia, 2013, 19, 720-726.	2.1	21

#	Article	IF	Citations
91	Inherited Bleeding Disorders in the Obstetric Patient. Transfusion Medicine Reviews, 2018, 32, 237-243.	2.0	21
92	Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review. Thrombosis Research, 2018, 163, 138-145.	1.7	20
93	Longâ€term safety and efficacy results from the phase 3b, openâ€label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia, 2020, 26, e168-e178.	2.1	20
94	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	2.3	20
95	Diagnosis and management of thrombosis in pregnancy. Birth Defects Research Part C: Embryo Today Reviews, 2015, 105, 185-189.	3.6	19
96	Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis. Thrombosis and Haemostasis, 2020, 120, 728-736.	3.4	19
97	Approaches to successful total knee arthroplasty in haemophilia A patients with inhibitors. Haemophilia, 2002, 8, 706-710.	2.1	18
98	A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease. Haemophilia, 2016, 22, e562-e564.	2.1	18
99	Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a. Blood, 2020, 136, 12-12.	1.4	18
100	Plasminogen Activator Inhibitorâ€1 Expression by Brain Microvessel Endothelial Cells Is Inhibited by Elevated Glucose. Journal of Neurochemistry, 1994, 63, 903-909.	3.9	17
101	Defining effective therapies in transfusion medicine and hemostasis: new opportunities with the TMH Network. Transfusion, 2005, 45, 1404-1406.	1.6	17
102	Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices. Nature Communications, 2021, 12, 2182.	12.8	17
103	How we treat: Haematuria in adults with haemophilia. Haemophilia, 2010, 16, 683-685.	2.1	16
104	Whole-genome association analyses of sleep-disordered breathing phenotypes in the NHLBI TOPMed program. Genome Medicine, 2021, 13, 136.	8.2	16
105	Balance, falls, and exercise: Beliefs and experiences in people with hemophilia: A qualitative study. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 147-154.	2.3	14
106	Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A. Blood, 2019, 134, 2060-2060.	1.4	14
107	von Willebrand factor proteolysis by ADAMTS-13 in patients on left ventricular assist device support. Journal of Heart and Lung Transplantation, 2017, 36, 477-479.	0.6	13
108	Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII. PLoS ONE, 2020, 15, e0233576.	2.5	13

#	Article	IF	Citations
109	RsaI RFLP in the human von Willebrand factor gene. Nucleic Acids Research, 1987, 15, 5909-5909.	14.5	12
110	Chronic hepatitis B and other correlates of spontaneous clearance of hepatitis C virus among HIV-infected people with hemophilia. Aids, 2007, 21, 1631-1636.	2.2	12
111	Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A. Haemophilia, 2013, 19, 595-601.	2.1	12
112	Tumor necrosis factor-alpha modulation of glycoprotein Ib alpha expression in human endothelial and erythroleukemia cells. Blood, 1992, 80, 153-161.	1.4	12
113	<scp>N</scp>â€Acetylcysteine: an old drug, a new insight, a potentially effective treatment for thrombotic thrombocytopenic purpura. Transfusion, 2014, 54, 1205-1207.	1.6	11
114	Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency. Molecular Therapy - Methods and Clinical Development, 2020, 19, 486-495.	4.1	11
115	The critical need for postmarketing surveillance in gene therapy for haemophilia. Haemophilia, 2021, 27, 126-131.	2.1	11
116	Nonsense mutation in exon V of the factor XI gene does not abolish platelet factor XI expression. British Journal of Haematology, 2000, 111, 91-95.	2.5	11
117	BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer. Blood, 2018, 132, 636-636.	1.4	11
118	Percutaneous Interventions in the Coagulopathic Patient. Seminars in Interventional Radiology, 2005, 22, 88-94.	0.8	10
119	Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. The Cochrane Library, 2020, 2020, CD011441.	2.8	10
120	Thrombophilia: What's a Practitioner to Do?. Hematology American Society of Hematology Education Program, 2001, 2001, 322-338.	2.5	10
121	Randomized, Prospective Clinical Trial of rFVIIa for Secondary Prophylaxis in Hemophilia Patients with Inhibitors.. Blood, 2006, 108, 766-766.	1.4	10
122	Total Knee Arthroplasty Using Recombinant Factor VII in Hemophilia-A Patients with Inhibitors: A Report of Three Cases. Journal of Bone and Joint Surgery - Series A, 2004, 86, 2519-2521.	3.0	10
123	Results of genetic analysis of 11â€‰341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States. Journal of Thrombosis and Haemostasis, 2022, 20, 2022-2034.	3.8	10
124	Feasibility of the Von Willebrand disease PREVENT trial. Thrombosis Research, 2017, 156, 8-13.	1.7	9
125	Comprehensive Nâ€•and Oâ€glycosylation mapping of human coagulation factor V. Journal of Thrombosis and Haemostasis, 2020, 18, 1884-1892.	3.8	9
126	Evaluation of Cell Types and Morphologies in Sickle Cell Disease with an Imaging Flow Cytometer. Blood, 2015, 126, 972-972.	1.4	9

#	Article	IF	Citations
127	Monitoring target specific anticoagulants. Journal of Thrombosis and Thrombolysis, 2013, 35, 387-390.	2.1	8
128	Preoperative management of factor XI deficiency with therapeutic plasma exchange: A case report and literature review. Journal of Clinical Apheresis, 2016, 31, 579-583.	1.3	8
129	Site-Specific N- and O-Glycosylation Analysis of Human Plasma Fibronectin. Frontiers in Chemistry, 2021, 9, 691217.	3.6	8
130	Parvovirus B19 quiescence during the course of human immunodeficiency virus infection in persons with hemophilia. , 1997, 56, 248-251.		7
131	Arterial shear stress stimulates surface expression of the endothelial glycoprotein Ib complex. , 1999, 73, 508-521.		7
132	Normal cleavage of von Willebrand factor by ADAMTS-13 in the absence of factorÂVIII in patients with severe hemophiliaÂA. Journal of Thrombosis and Haemostasis, 2013, 11, 1769-1772.	3.8	7
133	What is the effect of rivaroxaban on routine coagulation tests?. Hematology American Society of Hematology Education Program, 2014, 2014, 334-336.	2.5	7
134	Microvascular disease in diabetes mellitus. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 70-75.	1.5	7
135	Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. Haemophilia, 2013, 19, e151-66.	2.1	6
136	Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations. International Journal of Hematology, 2017, 106, 704-710.	1.6	6
137	Hepatitis C in haemophilia: time for treatment for all. Haemophilia, 2017, 23, 180-181.	2.1	6
138	The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors. Haemophilia, 2019, 25, 590-594.	2.1	6
139	A plasmid mediating production of a beta-lactamase by Stenotrophomonas maltophilia. Current Therapeutic Research, 1995, 56, 152-162.	1.2	5
140	Progress toward meeting the needs of adolescent females with bleeding disorders. Haemophilia, 2016, 22, 196-198.	2.1	5
141	Whole Genome Sequencing Identifies CRISPLD2 as a Lung Function Gene in Children With Asthma. Chest, 2019, 156, 1068-1079.	0.8	5
142	ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A. Blood, 2018, 132, 1192-1192.	1.4	5
143	Similarity in Joint Function Limitation in Type 3 VWD and Moderate Hemophilia A. Blood, 2008, 112, 426-426.	1.4	5
144	Human Endothelial Cells in Culture and In Vivo Express on Their Surface All Four Components of the Glycoprotein Ib/IX/V Complex. Blood, 1997, 90, 2660-2669.	1.4	5

#	Article	IF	Citations
145	Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII. Blood Advances, 2022, 6, 4271-4282.	5.2	5
146	False normal von Willebrand factor activity by monoclonal antibody-based ELISA in a patient with type 2A(IID) von Willebrand disease. Thrombosis and Haemostasis, 2011, 106, 1224-1225.	3.4	4
147	An algorithmic approach to peripheral artery disease in hemophilia. Blood Coagulation and Fibrinolysis, 2012, 23, 23-29.	1.0	4
148	Direct Oral Anticoagulants. Hematology/Oncology Clinics of North America, 2016, 30, 995-1006.	2.2	4
149	First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Î‘. Blood, 2020, 136, 8-8.	1.4	4
150	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood, 2014, 124, 2836-2836.	1.4	4
151	A Pilot Study of High-Dose N-Acetylcysteine Infusion in Patients with Sickle Cell Disease. Blood, 2016, 128, 1299-1299.	1.4	4
152	Potential Mechanisms for Enhanced Activity of Von Willebrand Factor in Patients with Sickle Cell Disease. Blood, 2016, 128, 3716-3716.	1.4	4
153	Laboratory evaluation of von Willebrand disease. Clinical Chemistry, 1995, 41, 489-490.	3.2	3
154	von Willebrand Disease. , 2013, , 90-102.		3
155	Monitoring target-specific oral anticoagulants. Hematology American Society of Hematology Education Program, 2014, 2014, 329-333.	2.5	3
156	Prevention of bleeding in hemophilia patients with high-titer inhibitors. Expert Review of Hematology, 2015, 8, 375-382.	2.2	3
157	Defining von Willebrand disease. Blood, 2016, 127, 2373-2374.	1.4	3
158	von Willebrand disease Outreach into Integrated Care Education (VOICE): a call to action. Haemophilia, 2017, 23, e370-e373.	2.1	3
159	Impacting inhibitor development in hemophilia A. Blood, 2017, 130, 1689-1690.	1.4	3
160	Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis. Blood, 2016, 128, 2576-2576.	1.4	3
161	Falls and associated complications in adults with haemophilia. The Journal of Haemophilia Practice, 2016, 3, 37-42.	0.4	3
162	A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). Journal of Blood Medicine, 2021, Volume 12, 883-896.	1.7	3

#	Article	IF	Citations
163	Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice. Blood Advances, 2020, 4, 5722-5734.	5.2	3
164	Phenotypic analysis of erythrocytes in sickle cell disease using imaging flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 448-457.	1.5	3
165	Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. Blood Advances, 2022, 6, 3735-3745.	5.2	3
166	An unusual case of toe ulceration. Vascular Medicine, 2006, 11, 35-37.	1.5	2
167	von Willebrand disease: treatment with or without factor VIII?. Journal of Thrombosis and Haemostasis, 2007, 5, 1113-1114.	3.8	2
168	Genetic analysis of bleeding disorders. Haemophilia, 2016, 22, 79-83.	2.1	2
169	Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease. Blood Cells, Molecules, and Diseases, 2020, 80, 102369.	1.4	2
170	Making Knowledge Hereditary: Publicâ€“Private Partnership Drives Progress in Rare Disease Community. Social Marketing Quarterly, 2020, 26, 218-228.	1.7	2
171	Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII. Molecular Therapy - Methods and Clinical Development, 2020, 17, 328-336.	4.1	2
172	How do Iâ€¦ facilitate a rapid response to a public health emergency requiring plasma collection with a publicâ€“private partnership?. Transfusion, 2021, 61, 2814-2824.	1.6	2
173	Phase II Trial of Rituximab in the Treatment of Inhibitors in Congenital Hemophilia A: Results of the RICH Study. Blood, 2011, 118, 27-27.	1.4	2
174	Healthcare Utilization and Health Related Quality of Life in Persons with Von Willebrand Disease. Blood, 2020, 136, 3-4.	1.4	2
175	Results of Genetic Analysis of 11,341 Participants Enrolled in the My Life, Our Future (MLOF) Hemophilia Genotyping Initiative. Blood, 2020, 136, 19-19.	1.4	2
176	Design of the Von Willebrand Factor in Pregnancy (VIP) Study. Blood, 2020, 136, 29-29.	1.4	2
177	Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophiliaâ€”Hematology Utilization Group Study Part VII (HUGS VII). Journal of Blood Medicine, 2022, Volume 13, 229-241.	1.7	2
178	Microvascular disease in diabetes mellitus. Coronary Artery Disease, 1996, 7, 702-707.	0.7	1
179	The Bernard-Soulier Syndrome. Trends in Cardiovascular Medicine, 1997, 7, 239-244.	4.9	1
180	To GpIb or not to GpIb. Blood, 1998, 92, 339-340.	1.4	1

#	Article	IF	Citations
181	Uncertain times for research on hemophilia and allied disorders. Journal of Thrombosis and Haemostasis, 2006, 4, 681-681.	3.8	1
182	Superficial venous thrombosis: cause for concern. Blood, 2013, 122, 1691-1692.	1.4	1
183	Atherosclerosis is not a risk factor for antiplatelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery. Thrombosis and Haemostasis, 2014, 111, 1191-1193.	3.4	1
184	Inhibitors in Hemophilias. , 2018, , 2023-2033.e5.		1
185	Diagnosis and management of von Willebrand disease: A communityâ€wide effort to deliver evidenceâ€based clinical practice guidelines. Haemophilia, 2021, 27, 181-183.	2.1	1
186	Parvovirus B19 quiescence during the course of human immunodeficiency virus infection in persons with hemophilia. American Journal of Hematology, 1997, 56, 248-251.	4.1	1
187	Efficacy and Safety Results from a Phase 3b, Open-Label, Multicenter, Continuation Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A. Blood, 2018, 132, 2483-2483.	1.4	1
188	Intake of Omega-3 Fatty Acids Suppresses Shear-Induced Platelet Aggregation and Reduces Lipid Raft Localization of the Platelet Glycoprotein Ib-IX-V Complex. Blood, 2011, 118, 1128-1128.	1.4	1
189	Novel Diagnostic Assays for Heparin-Induced Thrombocytopenia. Blood, 2012, 120, 267-267.	1.4	1
190	Von Willebrand Factor to Prevent Postpartum Hemorrhage. Blood, 2016, 128, 1400-1400.	1.4	1
191	Novel Approach to and Results of Genetic Analysis of 3000 Hemophilia Patients Enrolled in the MyLifeOurFuture Initiative. Blood, 2016, 128, 205-205.	1.4	1
192	Secondary Prophylaxis with rFVIIa Improves Quality of Life of Hemophilia Patients with Inhibitors and Frequent Bleeds.. Blood, 2006, 108, 1028-1028.	1.4	1
193	Novel Structural Variants Originating in F8 Non-Coding Regions in Previously Unresolved Cases of Severe Hemophilia A. Blood, 2018, 132, 379-379.	1.4	1
194	Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial. Blood, 2019, 134, 1130-1130.	1.4	1
195	Clingen Coagulation Factor Deficiency Variant Curation Expert Panel: Meeting the Need for Recommendations to Curate Variants in the Coagulation Factor Genes. Blood, 2019, 134, 5794-5794.	1.4	1
196	Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Journal of Cardiothoracic and Vascular Anesthesia, 1997, 11, 804.	1.3	0
197	Nonsense mutation in exon V of the factor XI gene does not abolish platelet factor XI expression. British Journal of Haematology, 2000, 111, 91-95.	2.5	0
198	5B.3 Counseling of women with thrombophilia. Thrombosis Research, 2007, 119, S67-S68.	1.7	0

#	Article	IF	Citations
199	Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease. Haemophilia, 2009, 15, 131-134.	2.1	0
200	Thrombotic Risk of Contraceptives and Other Hormonal Therapies. , 2013, , 603-615.		0
201	The Therapeutic Use of Plasma Components and Derivatives. , 2014, , 3171-3181.		0
202	Characteristics Associated With Annual Bleeding Frequency Among Hemophilia Patients In The United States. Value in Health, 2015, 18, A682.	0.3	0
203	Transfusion Medicine in Obstetrics. Transfusion Medicine Reviews, 2018, 32, 203-204.	2.0	0
204	von Willebrand Disease. , 2019, , 93-107.		0
205	Thrombotic Risk of Contraceptives and Other Hormonal Therapies. , 2019, , 637-650.		0
206	Thrombophilia: What's a Practitioner to Do?. Hematology American Society of Hematology Education Program, 2001, 2001, 322-338.	2.5	0
207	Von Willebrand Factor Levels Do Not Increase with Age in Patients with Type 1 Von Willebrand Disease.. Blood, 2004, 104, 4028-4028.	1.4	0
208	Acquired Hemophilia: Analysis of the Experience of a Regional Hemophilia Center.. Blood, 2006, 108, 4055-4055.	1.4	0
209	Treatment of Acute Bleeds in Acquired Hemophilia: Analysis from the Hemophilia Research Society (HRS) and Hemophilia and Thrombosis Research Society (HTRS) Registry.. Blood, 2008, 112, 2285-2285.	1.4	0
210	Normal Cleavage of Von Willebrand Factor by ADAMTS13 In the Absence of Factor VIII In Patients with Severe Hemophilia A. Blood, 2010, 116, 2114-2114.	1.4	0
211	Treatment of Pregnant Female with Mesenteric Vein Thrombosis and History of Spontaneous Fetal Losses. , 2011, 8, .		0
212	Factor VIII Mutation and Desmopressin-Responsiveness in 63 Patients with Mild Hemophilia A. Blood, 2011, 118, 1203-1203.	1.4	0
213	Pregnancy-Induced Shifts in Von Willebrand Factor (VWF) Parameters Support a Prolongation in VWF Survival. Blood, 2011, 118, 33-33.	1.4	0
214	Recombinant Factor VIII Combined With Recombinant Von Willebrand Factor In Patients With Severe Hemophilia A: A Prospective Clinical Study Of Safety and Pharmacokinetics. Blood, 2013, 122, 336-336.	1.4	0
215	Quantitative Analysis of Small Molecular Weight Thiols and Disulfides in Blood from a Sickle Cell Disease Patient Infused with N-Acetyl-L-Cysteine. Blood, 2014, 124, 2662-2662.	1.4	0
216	Brain-Derived Microparticles Induce Systemic Coagulation Associated with Traumatic Brain Injury. Blood, 2014, 124, 1497-1497.	1.4	0

#	Article	IF	Citations
217	An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia a. Blood, 2015, 126, 3522-3522.	1.4	0
218	Thrombotic Disorders. , 2016, , 439-446.		0
219	Prophylaxis in Patients with Hemophilia a and Its Impact on Quality of Life Using the Specific Index Haem-a-Qol at a Hospital in Paraguay. Blood, 2016, 128, 4959-4959.	1.4	0
220	Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a. Blood, 2016, 128, 1413-1413.	1.4	0
221	A Quantitative Assay of In Vivo Cleavage of Von Willebrand Factor By ADAMTS13 Reveals Excessive Cleavage in Type 2B Von Willebrand Disease and Diminished Cleavage in Thrombotic Thrombocytopenic Purpura. Blood, 2016, 128, 2532-2532.	1.4	0
222	Miscellaneous Questions. , 0, , 206-206.		0
223	Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study. Blood, 2018, 132, 2479-2479.	1.4	0
224	Effect of Intravenous and Oral N-Acetylcysteine Treatment in a Patient with Sickle Cell Disease at Disease Baseline. Blood, 2018, 132, 4911-4911.	1.4	0
225	A Multi-Omics Approach to X-Chromosome Inactivation (XCI) Identifies Severe Xci Skewing in Female Genetic Carriers of Hemophilia. Blood, 2020, 136, 19-20.	1.4	0
226	Hematology Utilization Group Studies Part VII (HUGS VII): Costs and Impact of Disease in Older Persons with Hemophilia. Blood, 2020, 136, 35-36.	1.4	0